Data-driven breast cancer screening illustration

Decoding Breast Cancer Screening: What Danish Data Reveals

Lena Voss monogram
Lena Voss in Health & Wellness October 2026 • 5 min read.

"Unveiling the Danish Quality Database of Mammography Screening (DKMS) and its impact on breast cancer detection and care."


Breast cancer is a significant health concern for women worldwide, and Denmark is no exception. With approximately 4,500 new cases diagnosed each year, it's the most common cancer among Danish women. Breast cancer accounts for a substantial portion of all cancer diagnoses and deaths, underscoring the need for effective screening and treatment strategies.

Mammography screening plays a vital role in early breast cancer detection, offering the potential to improve prognosis and reduce mortality rates. Studies have consistently shown that organized mammography screening programs can significantly decrease breast cancer mortality. However, the extent of this reduction remains a topic of discussion and ongoing research.

In Denmark, a nationwide mammography screening program was launched to provide biennial screenings to all women aged 50-69 years. To monitor and evaluate the program's effectiveness, the Danish Quality Database of Mammography Screening (DKMS) was established. This database serves as a valuable tool for assessing the quality of screening practices, identifying areas for improvement, and conducting research to optimize breast cancer outcomes.

AI Search Multiple angles on this topic

A Cautious Starting Point

The supplied material does not provide Danish breast-cancer screening statistics, prevalence figures, mortality data, or estimates of screening impact. As a result, no specific numerical conclusion can be drawn here. Any account of current outcomes would require dedicated epidemiological or national screening sources.

Evidence Boundaries

The supplied sources do not describe breast-cancer screening methods or their clinical limitations. They instead concern Microsoft Ink Canvas, SQL Server migration, Windows driver updates, and the Windows Insider Program. These materials therefore cannot substantiate claims about mammography, ultrasound, MRI, screening intervals, false positives, or overdiagnosis.

Historical Context Requires Dedicated Sources

The supplied material does not document the history of breast-cancer screening or identify relevant milestones and foundational discoveries. It therefore cannot support a chronology of mammography, screening policy, or diagnostic innovation. A reliable historical account would require medical-history or screening-program sources.

The Danish Quality Database: A Deep Dive

Data-driven breast cancer screening illustration

Established in 2007, the DKMS is designed to monitor and evaluate the quality and impact of the nationwide mammography screening program in Denmark. It aims to assess the effectiveness of the screening program and, over time, evaluate its impact on breast cancer-specific mortality. The database collects data on various aspects of the screening process, including participation rates, detection rates, and treatment outcomes.

The steering committee for the DKMS has defined eleven organizational and clinical quality indicators and standards to monitor the Danish breast cancer screening program. These indicators are assessed at both national and regional levels, providing a comprehensive overview of the program's performance. Here's a closer look at some of the key quality indicators:

  • Participation Rate: A high participation rate is crucial for screening programs to effectively reduce breast cancer morbidity and mortality. The DKMS monitors the proportion of invited women who participate in mammography screening.
  • Screening Interval: Monitoring the interval between screens is important for detecting tumors at an early stage. The DKMS tracks the number of women who are re-invited for screening within the recommended timeframe.
  • Time to Result: Timely communication of screening results is essential to minimize anxiety. The DKMS monitors the number of women who receive their screening results within a specified timeframe.
  • Recall Rate: A low recall rate, indicating fewer false positives, helps reduce unnecessary costs and anxiety. The DKMS monitors the proportion of screened women who are recalled for further examination.
  • Invasive Breast Tumors: The DKMS tracks the proportion of invasive cancers among all detected cancers to minimize the risk of over-diagnosis and over-treatment.
  • Node-Negative Cancers: Detecting cancer at an early stage increases the likelihood of negative axillary status. The DKMS monitors the number of women with invasive node-negative cancers.
  • Small Cancers: The percentage of small cancers detected is a key indicator of radiological quality. The DKMS monitors the number of women with small invasive cancers (≤1 cm).
  • Breast-Conserving Therapy: Mammography screening can lead to earlier cancer detection, increasing the potential for breast-conserving therapy. The DKMS monitors the number of women treated with breast-conserving therapy.
AI Search Multiple angles on this topic

No Relevant Research Identified

The listed sources concern airport parking and airport services rather than breast-cancer screening research. The Parking Spot reports more than two decades of off-site, near-airport parking leadership, while Rogue Valley International–Medford Airport provides travel and parking information. Airport Parking Reservations and SpotHero describe booking, cancellation, shuttle, comparison, and pre-payment services, but none supplies clinical research or reviews.

Source Mismatch

The supplied sources do not address counterarguments, failures, or harms associated with breast-cancer screening. Colorado State University’s Canvas materials describe announcements, accessibility support, instructor assistance, support forms, and grading schemes. Those details cannot establish evidence about screening errors, missed cancers, false-positive results, or program limitations.

Comparisons Require Clinical Data

The listed sources discuss using Google Colab with Google Drive and local files, including accessing files shared with me, resolving a missing google.colab module, and reading or writing local files. They do not compare breast-cancer screening technologies, Danish and international programs, or patient outcomes. No clinical comparison can therefore be drawn from this material.

Data for the DKMS is sourced from various national registries, including the Danish National Pathology Registry (DNPR) and the National Registry of Patients. These registries provide detailed information on biopsies, cancer diagnoses, surgical procedures, and treatment outcomes. By linking data from these sources using the civil registration number, the DKMS can create a comprehensive picture of the screening process and its impact on women's health.

The Future of Breast Cancer Screening in Denmark

The DKMS is a valuable resource for improving the quality of breast cancer screening and conducting research in the field. While the initial data has some limitations, the ongoing collection of data will provide further insights into the long-term impact of the screening program. By continuing to monitor quality indicators and address areas for improvement, Denmark can further optimize its breast cancer screening program and improve outcomes for women.

AI Search Multiple angles on this topic

Anatomy Is Not Screening Evidence

The supplied sources describe breast anatomy and breastfeeding physiology rather than breast-cancer screening. They state that breasts contain structures involved in milk production and that hormones including estrogens, progesterone, and prolactin contribute to development during pregnancy. They also describe oxytocin-driven milk flow during breastfeeding, but these facts do not establish screening effectiveness, diagnostic accuracy, or Danish health-system outcomes.

Future Directions Remain Open

The supplied material does not discuss future developments in breast-cancer screening. It provides no evidence about emerging imaging technologies, artificial intelligence, biomarkers, personalized screening, or Danish policy changes. Specific forecasts would therefore be speculative without dedicated research sources.

Variation Matters

Healthline reports that the exterior of human breasts is broadly similar, while breast size, shape, and function vary significantly between the sexes. This observation provides general anatomical context but does not explain systemic challenges in screening access, quality, or outcomes. It also cannot by itself support conclusions about how anatomical variation affects screening performance.

Human Impact Needs Direct Evidence

The supplied material contains no patient accounts, Danish screening experiences, or evidence about how screening affects individuals and communities. It therefore cannot substantiate claims about anxiety, reassurance, treatment decisions, access barriers, or lived outcomes. Those dimensions require patient-centered studies or health-service research.

First-round participation and screening indicators

  • 77.4% of invited women participatedOf 670,039 women invited, 518,823 attended screening, a participation rate of 77.4%.[1]
  • 73% and 65%Participation varied by region: it was 73% in the Capital Region and 65% in North Denmark, while the other regions met the greater-than-75% standard.[2]
  • 36% and 80%Small cancers made up 36% of cases, and 80% of women with invasive cancer received breast-conserving therapy.[1]
  • 1:6.3The ratio of surgery for benign to malignant lesions was 1:6.3.[1]

What the first round's indicators add up to

The participation total met the program’s stated threshold overall, but the regional figures show that this aggregate did not describe every region equally. These are measures of attendance, not evidence that screening reduced deaths.[1] [2]

The cancer and treatment indicators describe what was detected and how some cases were treated. They are quality-monitoring measures from the first round, rather than a direct test of the program’s effect on mortality.[1] [2]

Where the first-round evidence is weakest

  • The evaluation covered the initial screening round, so it could not yet assess later screening intervals or cancers arising between screens.[2]
  • Radiation-dose data were not available for this evaluation, leaving that indicator unassessed.[1]
  • Some women who had opted out of earlier local programs were not invited nationally, which means invitation did not encompass every otherwise eligible woman.[2]

The first-round DKMS study at a glance

PopulationDanish women aged 50–69 years invited for mammography screening[1]
Sample size670,039 invited; 518,823 participated[1]
Main outcomeQuality indicators for the Danish breast cancer screening program[1]
Confidence interval95% confidence intervals were calculated for each quality indicator[1]
FundingScreening program and database financed by the Danish health care system[1]
Times cited27[1]

How the DKMS findings relate to later work

Later publications cite the DKMS as the system for annual monitoring and describe invitations as regionally administered, with invitation and screening details transferred to the database.[3]

What the DKMS leaves to be resolved

  • How did the indicators change across later screening rounds, once repeated invitations and follow-up could be assessed?[2]
  • What was the program’s effect on breast-cancer-specific mortality after sufficient follow-up?[1]

Short answers about this DKMS evaluation

What did the database track?

Its eleven indicators covered organizational and clinical aspects, including participation, results timing, recalls, cancer features, treatment, and benign-to-malignant surgery.[1]

Sources

  1. Existing data sources for clinical epidemiology: the Danish Quality Database of Mammography Screening (Informa UK Limited, 2013)
  2. Existing data sources for clinical epidemiology: the Danish Quality Database of Mammography Screening (Europe PMC, 2013)
  3. University of Southern Denmark Morbidity as a predictor for participation in the Danish national mammography screening program A cross-sectional study (2020)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.2147/clep.s40484, Alternate LINK

Title: Existing Data Sources For Clinical Epidemiology: The Danish Quality Database Of Mammography Screening

Subject: Epidemiology

Journal: Clinical Epidemiology

Publisher: Informa UK Limited

Authors: Vivian Langagergaard, Garne, Vejborg, Schwartz, Bak, Lernevall, Mogensen, Larsson, Andersen, Mikkelsen

Published: 2013-03-01

Everything You Need To Know

1

What exactly is the Danish Quality Database of Mammography Screening (DKMS)?

The Danish Quality Database of Mammography Screening (DKMS) is a nationwide database established in 2007 in Denmark. Its purpose is to monitor and evaluate the quality and effectiveness of the country's mammography screening program. It collects data on various aspects of the screening process, such as participation rates, detection rates, and treatment outcomes. The DKMS aims to assess the overall impact of the screening program and, over time, evaluate its effect on breast cancer-specific mortality. By doing so, it provides valuable insights into the screening process, and its impact on women's health. The data from the DKMS is sourced from national registries, including the Danish National Pathology Registry (DNPR) and the National Registry of Patients. These registries provide information on biopsies, cancer diagnoses, surgical procedures, and treatment outcomes.

2

Why is the participation rate such an important factor in mammography screening programs?

Participation rate in mammography screening is crucial because it directly impacts the program's ability to reduce breast cancer morbidity and mortality. A higher participation rate ensures that a larger proportion of the target population is screened, increasing the likelihood of detecting breast cancer at an early stage when treatment is more effective. It's one of the eleven organizational and clinical quality indicators that the steering committee for the DKMS uses to monitor the Danish breast cancer screening program. By monitoring the proportion of invited women who participate in mammography screening, the DKMS can assess the program's reach and identify areas where efforts to encourage participation may be needed. Addressing barriers to participation is essential for maximizing the benefits of mammography screening and improving outcomes for women.

3

What is the 'recall rate,' and why is it important to monitor in breast cancer screening programs?

The recall rate is the proportion of screened women who are recalled for further examination after a mammogram. It's significant because a lower recall rate indicates fewer false positives, which helps reduce unnecessary costs and anxiety for women. The DKMS monitors the recall rate to assess the accuracy and efficiency of the screening process. A high recall rate may suggest that the screening process is generating too many false positives, leading to unnecessary follow-up tests and potential distress for women. While the goal is to detect cancer early, minimizing false positives is also important to avoid unnecessary burden on both patients and healthcare resources. The DKMS helps to ensure that the mammography screening program strikes a balance between sensitivity and specificity.

4

Besides participation rate, what are some other specific quality measures being tracked?

Several quality indicators are tracked by the Danish Quality Database of Mammography Screening (DKMS) to ensure the effectiveness of the breast cancer screening program. These include: Participation Rate which measures the proportion of invited women who participate in screening, Screening Interval which monitors the time between screens, Time to Result which measures how quickly women receive their screening results, Recall Rate which indicates the proportion of women recalled for further examination, Invasive Breast Tumors which tracks the proportion of invasive cancers detected, Node-Negative Cancers which monitors the number of women with invasive node-negative cancers, Small Cancers which tracks the percentage of small cancers detected, and Breast-Conserving Therapy which monitors the number of women treated with breast-conserving therapy. Other clinical quality indicators and standards are also tracked at both national and regional levels, providing a comprehensive overview of the program's performance.

5

Where does the Danish Quality Database of Mammography Screening (DKMS) get its data?

The DKMS utilizes data from national registries like the Danish National Pathology Registry (DNPR) and the National Registry of Patients. These registries provide detailed information on biopsies, cancer diagnoses, surgical procedures, and treatment outcomes. The DKMS links data from these sources using the civil registration number to create a comprehensive picture of the screening process and its impact on women's health. The ability to integrate data from multiple sources is crucial for the DKMS to accurately assess the effectiveness of the screening program and identify areas for improvement. Without this data, it would be challenging to track the long-term outcomes of women who participate in mammography screening and to determine the true impact of the program on breast cancer mortality.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.